Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)

Plain-language summary

This study investigates biomarkers that could help diagnose hemophagocytic lymphohistiocytosis (HLH) in critically ill patients in intensive care. It enrolled critically ill patients aged 18 and older with suspected or diagnosed HLH. This was a non-phase diagnostic study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Charite University, Berlin, Germany

Start date

9/11/2018

Estimated completion

12/26/2022

Countries

Germany

Related genes

Locations

• Berlin, Germany

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Male or female critically ill patients
* At least 18 years old
* Suspected or diagnosed HLH

Exclusion Criteria:

* Female patients: Pregnancy
* Female patients: Breastfeeding